Importantly, a reduced STAT3 activity augments the antitumor effects of sunitinib, whereas the constitutive activation of a STAT3 mutant rescues tumor cell death [24], suggesting that STAT3 activation is a crucial downstream mediator that executes sunitinib’s effects. This evidence concerns the gene STAT3 and neoplasm.